![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://endpts.com/fda-approves-antibiotic-for-pneumonia-caused-by-hard-to-treat-bacteria/
https://endpts.com/adcomm-unanimously-recommends-entasis-bacterial-pneumonia-candidate-for-resistant-infections/
https://endpts.com/adcomm-unanimously-recommends-entasis-bacterial-pneumonia-candidate-for-resistant-infections/
https://www.globenewswire.com/news-release/2022/10/19/2537378/0/en/Entasis-Therapeutics-a-Wholly-Owned-Subsidiary-of-Innoviva-Presents-Efficacy-and-Safety-Data-from-Landmark-Phase-3-ATTACK-Trial-at-IDWEEK-2022.html
https://www.globenewswire.com/news-release/2022/10/12/2532897/0/en/Entasis-Therapeutics-a-Wholly-Owned-Subsidiary-of-Innoviva-Announces-Data-on-SUL-DUR-to-be-Presented-at-IDWeek-2022.html
https://www.globenewswire.com/news-release/2022/06/09/2459626/0/en/Entasis-Therapeutics-Presents-Data-on-Sulbactam-Durlobactam-and-ETX0462-at-2022-ASM-Microbe-Annual-Conference.html
https://seekingalpha.com/news/3841688-innoviva-to-acquire-entasis-therapeutics-for-220share
https://www.globenewswire.com/news-release/2022/04/27/2430102/0/en/Entasis-Therapeutics-Announces-First-Quarter-2022-Financial-Results-and-Provides-Business-Update.html